Free Trial

ADMA Biologics (ADMA) Stock Price, News & Analysis

+0.31 (+2.38%)
(As of 07/19/2024 ET)
Today's Range
50-Day Range
52-Week Range
2.83 million shs
Average Volume
3.41 million shs
Market Capitalization
$3.10 billion
P/E Ratio
Dividend Yield
Price Target

ADMA Biologics MarketRank™ Stock Analysis

Analyst Rating
3.25 Rating Score
8.3% Downside
$12.25 Price Target
Short Interest
3.14% of Shares Sold Short
Dividend Strength
News Sentiment
0.85mentions of ADMA Biologics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$1.07 M Sold Last Quarter
Proj. Earnings Growth
From $0.35 to $0.53 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.62 out of 5 stars

Medical Sector

406th out of 896 stocks

Biological Products, Except Diagnostic Industry

61st out of 151 stocks

ADMA stock logo

About ADMA Biologics Stock (NASDAQ:ADMA)

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

ADMA Stock Price History

ADMA Stock News Headlines

Rare signal predicts 50% market drop - before election
The market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED will cut rates any day now. But there's one indicator that's flashing a BIG warning sign to investors.
Add These 5 Hot Biotech Stocks In July
ADMA Biologics (NASDAQ:ADMA) Sets New 1-Year High at $13.02
Rare signal predicts 50% market drop - before election
The market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED will cut rates any day now. But there's one indicator that's flashing a BIG warning sign to investors.
Giving ADMA Biologics A Well-Deserved 'Booyah'
ADMA Biologics, Inc.
See More Headlines
Receive ADMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Pharmaceutical Products
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$258.21 million
Cash Flow
$0.05 per share
Book Value
$0.60 per share


Free Float
Market Cap
$3.10 billion
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Adam S. GrossmanMr. Adam S. Grossman (Age 47)
    Co-Founder, President, CEO, Interim CFO & Director
    Comp: $1.59M
  • Dr. Jerrold B. Grossman D.P.S. (Age 76)
    Ph.D., Co-Founder & Vice Chairman of the Board
    Comp: $90k
  • Ms. Kaitlin Kestenberg (Age 37)
    COO & Senior VP of Compliance
  • Mr. Drew Pantello
    Vice President of Marketing & Corporate Development
  • Ms. Cindy Petersen
    Executive Director of Human Resources
  • Mr. Skyler Bloom
    Senior Director of Business Development & Corporate Strategy
  • Mr. Brad Tade
    Vice President of Financial Operations

ADMA Stock Analysis - Frequently Asked Questions

How have ADMA shares performed this year?

ADMA Biologics' stock was trading at $4.52 at the beginning of the year. Since then, ADMA shares have increased by 195.6% and is now trading at $13.36.
View the best growth stocks for 2024 here

How were ADMA Biologics' earnings last quarter?

ADMA Biologics, Inc. (NASDAQ:ADMA) announced its quarterly earnings results on Thursday, May, 9th. The biotechnology company reported $0.08 earnings per share for the quarter, beating analysts' consensus estimates of $0.05 by $0.03. The business's revenue was up 43.9% compared to the same quarter last year.

What is Adam S. Grossman's approval rating as ADMA Biologics' CEO?

9 employees have rated ADMA Biologics Chief Executive Officer Adam S. Grossman on Adam S. Grossman has an approval rating of 29% among the company's employees. This puts Adam S. Grossman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are ADMA Biologics' major shareholders?

ADMA Biologics' top institutional shareholders include Assenagon Asset Management S.A. (1.46%), SG Americas Securities LLC (0.16%), Raymond James & Associates (0.12%) and First Hawaiian Bank (0.04%). Insiders that own company stock include Steve Elms, Adam S Grossman, Brian Lenz, Jerrold B Grossman, Young Kwon, Bryant Fong and Perceptive Advisors Llc.
View institutional ownership trends

How do I buy shares of ADMA Biologics?

Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of ADMA Biologics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ADMA Biologics investors own include Matinas BioPharma (MTNB), Pennsylvania Real Estate Investment Trust (PEI), Organigram (OGI), Tilly's (TLYS), Bionano Genomics (BNGO) and Novan (NOVN).

This page (NASDAQ:ADMA) was last updated on 7/21/2024 by Staff

From Our Partners